Company Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 1998 |
IPO Date | Feb 3, 2010 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 267 |
CEO | Thomas A. McCourt |
Contact Details
Address: 100 Summer Street, Suite 2300 Boston, Massachusetts 02110 United States | |
Phone | 617-621-7722 |
Website | ironwoodpharma.com |
Stock Details
Ticker Symbol | IRWD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001446847 |
CUSIP Number | 46333X108 |
ISIN Number | US46333X1081 |
Employer ID | 04-3404176 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Julie H. McHugh | Executive Chairman of the Board |
Thomas A. McCourt | Chief Executive Officer and Director |
Sravan Kumar Emany | Senior Vice President, Principal Financial Officer and Chief Financial Officer |
John Minardo | Senior Vice President, Chief Legal Officer and Secretary |
Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior Vice President and Head of Research and Drug Development |
Ronald Silver | Corporate Controller and Principal Accounting Officer |
Marcel Moulaison | Vice President of Technical Operations |
Greg Martini | Vice President of Strategic Finance and Investor Relations |
Beth Calitri | Head of Corporate Communications and Media Relations |
Mike Nanfito | Vice President of Sales and Sales Excellence |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 16, 2024 | 10-K | Annual Report |
Feb 15, 2024 | 8-K | Current Report |
Feb 9, 2024 | 144 | Filing |
Feb 9, 2024 | 144 | Filing |
Feb 9, 2024 | 144 | Filing |
Feb 9, 2024 | 144 | Filing |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |